Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 6 trials

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

5Total
Not Applicable (2)
P 2 (2)
P 3 (1)

Trial Status

Recruiting5
Active Not Recruiting1

Clinical Trials (6)

Showing 6 of 6 trials
NCT06509009Phase 2RecruitingPrimary

Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

NCT06095154Phase 3RecruitingPrimary

CTV Delineation Based Solely on Geometric Expansion From GTV in Nasopharyngeal Carcinoma

NCT05513573Phase 2Active Not RecruitingPrimary

Phase II Clinical Study to Compare the Efficacy and Safety of HLX07 + Serplulimab +Chemotherapy Versus Placebo + Serplulimab + Chemotherapy in First-Line Treatment of Patients With Recurrent or Metastatic NPC

NCT05858385RecruitingPrimary

Predictive Study on Acute Radiation Induced Oral Mucositis in Nasopharyngeal Carcinoma Patients

NCT06167109Not ApplicableRecruitingPrimary

NBI Combined With MRI to Guide CTV Optimization in Eccentric Nasopharyngeal Carcinoma

NCT05717790Not ApplicableRecruitingPrimary

Concurrent and Adjuvant Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation in Nasopharyngeal Carcinoma

Showing all 6 trials

Research Network

Activity Timeline